Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Proteome Res ; 20(1): 531-537, 2021 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-33226812

RESUMEN

The blood-brain barrier (BBB) is essential for cerebral homeostasis and controls the selective passage of molecules traveling in and out of the brain. Despite the crucial role of the BBB in a variety of brain diseases and its relevance for the development of drugs, there is little known about its molecular architecture. In particular, the composition of the basal lamina between the astrocytic end-feet and the endothelial cells is only partly known. Here, we present a proteomic analysis of the basal lamina of the human BBB. We combined laser capture microdissection with shotgun proteomics for selective enrichment and identification of specific proteins present in the cerebral microvasculature and arachnoidal vessels collected from normal human brain tissue specimens. Proteins found to be associated with the blood-brain barrier were validated by immunohistochemistry. Expression of membrane protein MLC1 was found in all brain barriers. Phosphoglucomutase-like protein 5 appeared to be variably present along the outer part of intracerebral vessels, and multidrug resistance protein 1 was identified in both intracerebral, as well as arachnoidal blood vessels. The results demonstrate the presence of so far unidentified proteins in the human BBB and illustrate topic differences in their expression. In conclusion, we showed that sample purification by microdissection followed by shotgun proteomics provides a list of proteins identified in the BBB. Subsequent immunohistochemistry detailed the respective expression sites of membrane protein MLC1 and phosphoglucomutase-related protein 5. The role of the identified proteins in the functioning of the BBB needs further investigations.


Asunto(s)
Barrera Hematoencefálica , Encéfalo , Células Endoteliales , Proteómica , Transporte Biológico , Humanos , Proteínas/metabolismo
2.
Gastroenterology ; 155(5): 1410-1415, 2018 11.
Artículo en Inglés | MEDLINE | ID: mdl-30063919

RESUMEN

BACKGROUND & AIMS: It is important to identify individuals with Lynch syndrome because surveillance programs can reduce their morbidity and mortality from colorectal cancer (CRC). We assessed the diagnostic yield of immunohistochemistry to detect Lynch syndrome in patients with advanced and multiple adenomas within our national CRC screening program. METHODS: We performed a prospective study of all participants (n = 1101; 55% male; median age, 66 years; interquartile range, 61-70 years) referred to the Erasmus MC in The Netherlands after a positive result from a fecal immunohistochemical test, from December 2013 to December 2016. Colon tissues were collected from patients with advanced adenomas, ≥4 nonadvanced adenomas, or CRC, and analyzed by immunohistochemistry to identify patients with loss of mismatch repair (MMR) proteins (MLH1, MSH2, MSH6, or PMS2): a marker of Lynch syndrome. Specimens from patients with loss of MLH1 were analyzed for MLH1 promoter hypermethylation. Patients with an MMR-deficient tumor or adenoma without MLH1 promoter hypermethylation were referred for genetic analysis. RESULTS: At colonoscopy, 456 patients (41%) (65% male; mean age, 67 years; interquartile range, 63-71 years) were found to have CRC and/or an adenoma eligible for analysis by immunohistochemistry. Of 56 CRCs, 7 (13%) had lost an MMR protein and 5 had hypermethylation of the MLH1 promoter. Analyses of tumor DNA revealed that 2 patients without MLH1 promoter hypermethylation had developed sporadic tumors. In total, 400 patients with adenomas were analyzed. Of the examined adenomas, 208 (52%) had a villous component and/or high-grade dysplasia: 186 (47%) had a villous component and 41 (10%) had high-grade dysplasia. Only 1 adenoma had lost an MMR protein. This adenoma was found to have 2 somatic mutations in MSH6. CONCLUSIONS: In a CRC screening program in The Netherlands for individuals aged 55 to 75 years, routine screening for Lynch syndrome by immunohistochemistry analysis of colon tissues from patients with advanced and multiple adenomas identified no individuals with this genetic disorder.


Asunto(s)
Adenoma/genética , Neoplasias Colorrectales Hereditarias sin Poliposis/genética , Neoplasias Colorrectales/genética , Reparación de la Incompatibilidad de ADN/genética , Detección Precoz del Cáncer , Anciano , Neoplasias Colorrectales/diagnóstico , Neoplasias Colorrectales Hereditarias sin Poliposis/diagnóstico , Proteínas de Unión al ADN/genética , Femenino , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Homólogo 1 de la Proteína MutL/genética , Regiones Promotoras Genéticas , Estudios Prospectivos
3.
Acta Neuropathol ; 135(4): 581-599, 2018 04.
Artículo en Inglés | MEDLINE | ID: mdl-29350274

RESUMEN

The discovery of genes and molecular pathways involved in the formation of brain metastasis would direct the development of therapeutic strategies to prevent this deadly complication of cancer. By comparing gene expression profiles of Estrogen Receptor negative (ER-) primary breast tumors between patients who developed metastasis to brain and to organs other than brain, we found that T lymphocytes promote the formation of brain metastases. To functionally test the ability of T cells to promote brain metastasis, we used an in vitro blood-brain barrier (BBB) model. By co-culturing T lymphocytes with breast cancer cells, we confirmed that T cells increase the ability of breast cancer cells to cross the BBB. Proteomics analysis of the tumor cells revealed Guanylate-Binding Protein 1 (GBP1) as a key T lymphocyte-induced protein that enables breast cancer cells to cross the BBB. The GBP1 gene appeared to be up-regulated in breast cancer of patients who developed brain metastasis. Silencing of GBP1 reduced the ability of breast cancer cells to cross the in vitro BBB model. In addition, the findings were confirmed in vivo in an immunocompetent syngeneic mouse model. Co-culturing of ErbB2 tumor cells with activated T cells induced a significant increase in Gbp1 expression by the cancer cells. Intracardial inoculation of the co-cultured tumor cells resulted in preferential seeding to brain. Moreover, intracerebral outgrowth of the tumor cells was demonstrated. The findings point to a role of T cells in the formation of brain metastases in ER- breast cancers, and provide potential targets for intervention to prevent the development of cerebral metastases.


Asunto(s)
Neoplasias Encefálicas/metabolismo , Neoplasias Encefálicas/secundario , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/patología , Proteínas de Unión al GTP/metabolismo , Linfocitos T/metabolismo , Adulto , Anciano , Animales , Barrera Hematoencefálica/metabolismo , Barrera Hematoencefálica/patología , Células Cultivadas , Técnicas de Cocultivo , Femenino , Proteínas de Unión al GTP/genética , Regulación Neoplásica de la Expresión Génica , Humanos , Ratones , Persona de Mediana Edad , Metástasis de la Neoplasia/fisiopatología , Trasplante de Neoplasias , Proteoma , ARN Mensajero/metabolismo
4.
J Cell Physiol ; 229(8): 967-73, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24374845

RESUMEN

The detection of co-localization of immunohistochemical markers in tissues or cells requires the application of the confocal laser scanning microscope (CLSM) to multiple immunofluorescence (MIF) stainings. CLSM is operationally sophisticated but requires time-consuming procedures of imaging and reconstruction, and a professional operator is required for manipulation of the microscopic system. Therefore, this technique is less suitable for the examination of many samples in a short time. Moreover, the technique only allows imaging of selected areas of a sample at one time and is not practical for fast panoramic mapping and tracking of whole tissue sections. Here we show a powerful high-throughput and operationally simple histological approach using the Hamamatsu NDP slide scanner (Hamamatsu Nanozoomer 2.0HT) and its viewing platform (NDP.Viewer). The approach not only enables fast mapping and tracking of overlapping spots or regions stained with multiple markers, but also offers panoramic screening of whole tissue sections with fully electronic manipulation for the visualization and analysis of any individual regions.


Asunto(s)
Procesamiento de Imagen Asistido por Computador/métodos , Inmunohistoquímica/métodos , Macrófagos/citología , Monocitos/citología , Transporte de Proteínas/fisiología , Animales , Biomarcadores/química , Biomarcadores/metabolismo , Regulación de la Expresión Génica , Humanos , Macrófagos/fisiología , Monocitos/fisiología
5.
J Cell Physiol ; 228(7): 1383-90, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23254765

RESUMEN

Literature data indicate that glioma stem cells may give rise to both tumor cells and endothelial progenitor cells (EPCs). Malignant glioma patients usually have increased levels of circulating (EPCs) and these cells are known to contribute to the glioma neovasculature. In this study we compared the intratumoral and circulating EPCs of glioma patients for a set of common glioma genotypical aberrations (amplification of EGFR; deletion of PTEN and aneusomy of chromosomes 7 and 10). We found that the EPCs present in the tumor tissues, not the circulating EPCs, share genetic aberrations with the tumor cells. EPCs with EGFR amplification were found in 46% and with PTEN deletion in 36% of the cases. EPCs with polysomy 7 and monosomy 10 were detected in 56% and 38% of the cases while centrosomal abnormalities in EPCs were found in 68% of the cases. The presence of genetic aberrations of glioma cells in intratumoral EPCs may point to transdifferentiation of glioma stem cells into EPCs. However, the tissue specific CD133 splice variant of blood EPCs was detected in the glioma tissues but not in control brains, suggestive of a blood origin of at least part of the intratumoral EPCs. The findings highlight the complexity of the cellular constituents of glioma neovascularization which should be taken into account when developing anti-angiogenic strategies for gliomas.


Asunto(s)
Neoplasias Encefálicas/genética , Neoplasias Encefálicas/patología , Aberraciones Cromosómicas , Células Endoteliales/patología , Glioma/genética , Glioma/patología , Células Madre Neoplásicas/patología , Adulto , Anciano , Aneuploidia , Neoplasias Encefálicas/irrigación sanguínea , Estudios de Casos y Controles , Cromosomas Humanos Par 10 , Cromosomas Humanos Par 7 , Femenino , Genes erbB-1 , Glioma/irrigación sanguínea , Humanos , Masculino , Persona de Mediana Edad , Células Neoplásicas Circulantes/patología , Fosfohidrolasa PTEN/genética
6.
J Proteome Res ; 10(11): 4902-10, 2011 Nov 04.
Artículo en Inglés | MEDLINE | ID: mdl-21879768

RESUMEN

We have sought for disease-related proteins that could predict the onset of Alzheimer's disease (AD) in a study population derived from the Rotterdam Scan Study, a population-based prospective cohort study designed to investigate the etiology and natural history of age-related brain changes in the elderly. The serum proteome of 43 persons who developed AD, after an average of 4.2 years (±2.6 years SD) after blood sampling, and 43 gender- and age-matched controls who remained dementia-free during follow-up was investigated by liquid chromatography mass spectrometry. We identified 61 differentially expressed peptides between presymptomatic AD and controls, 9 of which were derived from pregnancy zone protein (PZP). Quantitative measurements using a multiple reaction monitoring assay showed a significant increase in concentration of PZP in presymptomatic AD (34.3 ± 20.6 mg/L) compared with controls (23.6 ± 13.6 mg/L) (p = 0.006). The difference in PZP was significant in women. Immunohistochemical validation of the findings on brain tissue sections showed strong PZP expression in senile plaques and in microglial and glial cells in AD with only low expression in some scattered glial cells in controls.


Asunto(s)
Enfermedad de Alzheimer/sangre , Proteínas Gestacionales/sangre , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/diagnóstico , Enfermedad de Alzheimer/patología , Secuencia de Aminoácidos , Antracenos , Enfermedades Asintomáticas , Biomarcadores/sangre , Encéfalo/metabolismo , Encéfalo/patología , Estudios de Casos y Controles , Estudios de Cohortes , Diagnóstico Precoz , Femenino , Humanos , Masculino , Espectrometría de Masas , Datos de Secuencia Molecular , Fragmentos de Péptidos/química , Proteínas Gestacionales/química , Estudios Prospectivos
7.
Cancers (Basel) ; 13(12)2021 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-34203581

RESUMEN

BACKGROUND: Brain metastasis is considered one of the major causes of mortality in breast cancer patients. To invade the brain, tumor cells need to pass the blood-brain barrier by mechanisms that are partially understood. In primary ER-negative breast cancers that developed brain metastases, we found that some of the differentially expressed genes play roles in the T cell response. The present study aimed to identify genes involved in the formation of brain metastasis independently from the T cell response. METHOD: Previously profiled primary breast cancer samples were reanalyzed. Genes that were found to be differentially expressed were confirmed by RT-PCR and by immunohistochemistry using an independent cohort of samples. RESULTS: BOC, SPOCK2, and GJD3 were overexpressed in the primary breast tumors that developed brain metastasis. BOC expression was successfully validated at the protein level. SPOCK2 was validated at both mRNA and protein levels. SPOCK2 and GJD3 mRNA overexpression were also found to be associated with cerebral metastasis in an external online database consisting of 204 primary breast cancers. CONCLUSION: The overexpression of BOC, SPOCK2, and GJD3 is associated with the invasion of breast cancer into the brain. Further studies to determine their specific function and potential value as brain metastasis biomarkers are required.

8.
J Neuropathol Exp Neurol ; 79(8): 863-872, 2020 08 01.
Artículo en Inglés | MEDLINE | ID: mdl-32647861

RESUMEN

The expression of the matricellular protein periostin has been associated with glioma progression. In previous work we found an association of periostin with glioma angiogenesis. Here, we screen gliomas for POSTN expression and identify the cells that express periostin in human gliomas. In addition, we study the role of periostin in an in vitro model for angiogenesis. The expression of periostin was investigated by RT-PCR and by immunohistochemistry. In addition, we used double labeling and in situ RNA techniques to identify the expressing cells. To investigate the function of periostin, we silenced POSTN in a 3D in vitro angiogenesis model. Periostin expression was elevated in pilocytic astrocytoma and glioblastoma, but not in grade II/III astrocytomas and oligodendrogliomas. The expression of periostin colocalized with PDGFRß+ cells, but not with OLIG2+/SOX2+ glioma stem cells. Silencing of periostin in pericytes in coculture experiments resulted in attenuation of the numbers and the length of the vessels formation and in a decrease in endothelial junction formation. We conclude that pericytes are the main source of periostin in human gliomas and that periostin plays an essential role in the growth and branching of blood vessels. Therefore, periostin should be explored as a novel target for developing anti-angiogenic therapy for glioma.


Asunto(s)
Neoplasias Encefálicas/patología , Moléculas de Adhesión Celular/metabolismo , Glioma/patología , Neovascularización Patológica/metabolismo , Pericitos/metabolismo , Adulto , Anciano , Neoplasias Encefálicas/metabolismo , Femenino , Glioma/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Neovascularización Patológica/patología
9.
Proteomics Clin Appl ; 13(3): e1800181, 2019 05.
Artículo en Inglés | MEDLINE | ID: mdl-30417587

RESUMEN

PURPOSE: The objective of present study is to determine serum levels and placental distribution of two interacting proteins calcyclin and heat shock protein 90 in preeclampsia. EXPERIMENTAL DESIGN: Maternal serum levels of calcyclin and heat shock protein 90 are compared throughout pregnancy from the first trimester till term among women with preeclampsia (n = 43) and age-matched normotensive pregnant controls (n = 46). A serum-based 2D LC-MS assay using Parallel Reaction Monitoring is applied to quantify both calcyclin and heat shock protein 90. RESULTS: Serum levels of calcyclin are significantly lower in patients with preeclampsia in the second trimester of pregnancy as compared to controls (p < 0.05). Serum levels of heat shock protein 90 are significantly higher in patients with preeclampsia in the third trimester as compared to controls (p < 0.001). CONCLUSION AND CLINICAL RELEVANCE: Both interacting proteins calcyclin and heat shock protein 90 are notably changed in preeclamptic patients compared to controls. Calcyclin is already decreased before the onset of preeclampsia in the second trimester and HSP90 is strongly increased in the third trimester. This suggests that these proteins may play a role in the pathogenesis of preeclampsia and ought to be investigated in large cohort studies as molecular biomarkers.


Asunto(s)
Proteínas HSP90 de Choque Térmico/sangre , Placenta/metabolismo , Preeclampsia/sangre , Proteína A6 de Unión a Calcio de la Familia S100/sangre , Adulto , Estudios de Casos y Controles , Femenino , Humanos , Espectrometría de Masas , Preeclampsia/patología , Embarazo , Proteómica , Trofoblastos/metabolismo
10.
J Neuropathol Exp Neurol ; 66(12): 1118-23, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18090920

RESUMEN

The favorable response of oligodendrogliomas correlates well with characteristic chromosomal losses, of which loss of the short arm of chromosome 1 is most predictive. Oligodendrogliomas are histopathologically heterogeneous tumors and, in addition to the classic honeycomb histology, fields of nonclassic histology are often encountered. Information about the distribution of 1p loss in various regions of oligodendroglioma is, therefore, important to interpret findings in tumor biopsies. In this study we investigated the distribution of 1p loss in multiple fields in 24 biopsy specimens of oligodendroglioma consisting of classic and nonclassic histology by fluorescent in situ hybridization and loss of heterozygosity analysis. By fluorescent in situ hybridization analysis, loss of 1p was found in all fields examined in 37% of the tumor samples, and no loss was detected in 46%. In fields of classic oligodendroglial and polar spongioblastoma-like histology, significantly more loss for 1p was found (p < 0.001 and p < 0.01, respectively). Although fluorescent in situ hybridization analysis indicated heterogeneity for 1p loss in the other 17% of tumors, loss of heterozygosity analysis of these samples pointed to homogeneity of 1p status in all fields. The 1p status of the fields with classic histology significantly correlated with the status of the other fields in the same tumors (Spearman's rho 0.918, p < 0.001). These results point to genotypic homogeneity for 1p in oligodendroglial tumors.


Asunto(s)
Neoplasias Encefálicas/genética , Aberraciones Cromosómicas , Cromosomas Humanos Par 1 , Glioma/genética , Pérdida de Heterocigocidad , Oligodendroglioma/genética , Humanos , Hibridación Fluorescente in Situ/métodos , Análisis de Supervivencia
11.
Acta Neuropathol Commun ; 5(1): 4, 2017 01 10.
Artículo en Inglés | MEDLINE | ID: mdl-28073370

RESUMEN

The role of resident microglial cells in the pathogenesis and progression of glial tumors is still obscure mainly due to a lack of specific markers. Recently P2RY12, a P2 purinergic receptor, was introduced as a specific marker for microglial cells under normal and pathologic conditions. Here we analyzed the expression of P2RY12 in astrocytomas of various malignancy grades in relation to markers for M1 and M2 macrophage activation profiles by using two web-based glioma datasets and confocal immunohistochemistry to 28 astrocytoma samples grades II-IV. In the gliomas, P2RY12 immunoreactivity delineated CD68 negative cells with otherwise microglial features from CD68 positive tumor associated macrophages (TAMs). The presence of P2RY12 positive cells correlated positively with overall survival. P2RY12 mRNA levels and membrane-bound localization of P2RY12 were inversely correlated with increasing malignancy grade, and the expression site of P2RY12 shifted from cytoplasmic in low-grade gliomas, to nuclear in high-grade tumors. The cytoplasmic expression of P2RY12 was associated with the expression of M1 markers, characteristic of the pro-inflammatory macrophage response. In contrast, the nuclear localization of P2RY12 was predominant in the higher graded tumors and associated with the expression of the M2 marker CD163.We conclude that P2RY12 is a specific marker for resident microglia in glioma and its expression and localization correspond to tumor grade and predominant stage of M1/M2 immune response.


Asunto(s)
Astrocitoma/metabolismo , Astrocitoma/patología , Neoplasias Encefálicas/metabolismo , Neoplasias Encefálicas/patología , Microglía/metabolismo , Adulto , Antígenos CD/metabolismo , Antígenos de Diferenciación Mielomonocítica/metabolismo , Astrocitoma/genética , Astrocitoma/terapia , Biomarcadores de Tumor/metabolismo , Encéfalo/metabolismo , Encéfalo/patología , Neoplasias Encefálicas/genética , Neoplasias Encefálicas/terapia , Núcleo Celular/metabolismo , Núcleo Celular/patología , Citoplasma/metabolismo , Citoplasma/patología , Bases de Datos Factuales , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Inmunohistoquímica , Masculino , Microglía/patología , Microscopía Confocal , Persona de Mediana Edad , Clasificación del Tumor , ARN Mensajero/metabolismo , Análisis de Secuencia de ARN , Análisis de Supervivencia , Resultado del Tratamiento
12.
Neuro Oncol ; 19(5): 648-659, 2017 05 01.
Artículo en Inglés | MEDLINE | ID: mdl-28453746

RESUMEN

Background: The majority of glioma-associated microglia/macrophages have been identified as M2-type macrophages with immune suppressive and tumor supportive action. Recently, the extracellular adenosine deaminase protein Cat Eye Syndrome Critical Region Protein 1 (CECR1) was shown to regulate macrophage maturation. In this study, we investigate the role of CECR1 in the regulation of the glioma-associated macrophage response. Methods: Expression of CECR1 was assessed in human glioma samples. CECR1-mediated macrophage response was studied in vitro, using donor derived CD14+ monocytes and the THP-1 monocytic cell line. The response of the human glioma cell line U87 to conditioned medium of macrophages preconditioned with recombinant human CECR1 or CECR1 silencing was also assessed. Results: CECR1 was strongly expressed in high-grade gliomas (P < .001) and correlated positively with the M2 phenotype markers in tumor-associated microglia/macrophages (TAMs) (overall, P < .05). In vitro studies confirmed the presence of a significantly higher level of CECR1 expression in M2-like macrophages exposed to U87 conditioned medium (P < .001). CECR1 knockdown or stimulation of macrophages affected differentiation toward the M2-like phenotype. Stimulation of U87 cells with conditioned medium of CECR1 knockdown or stimulated macrophages affected tumor cell proliferation and migration, coinciding with altered intracellular signaling of mitogen-activated protein kinase (MAPK). In glioma tissue samples, CECR1 expression correlated with Ki67 and MAPK signaling protein. Conclusions: CECR1 is a potent regulator of TAM polarization and is consistently highly expressed by M2-type TAMs, particularly in high-grade glioma. Paracrine effects induced by CECR1 in M2-like TAMs activate MAPK signaling and stimulate the proliferation and migration of glioma cells.


Asunto(s)
Adenosina Desaminasa/metabolismo , Neoplasias Encefálicas/patología , Glioma/patología , Péptidos y Proteínas de Señalización Intercelular/metabolismo , Macrófagos/patología , Microglía/patología , Comunicación Paracrina , Neoplasias Encefálicas/metabolismo , Diferenciación Celular , Movimiento Celular , Proliferación Celular , Progresión de la Enfermedad , Glioma/metabolismo , Humanos , Macrófagos/metabolismo , Microglía/metabolismo , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Transducción de Señal , Células Tumorales Cultivadas
13.
PLoS One ; 10(12): e0144097, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26716838

RESUMEN

BACKGROUND: Gene expression profiling of tumors is a successful tool for the discovery of new cancer biomarkers and potential targets for the development of new therapeutic strategies. Reliable profiling is preferably performed on fresh frozen (FF) tissues in which the quality of nucleic acids is better preserved than in formalin-fixed paraffin-embedded (FFPE) material. However, since snap-freezing of biopsy materials is often not part of daily routine in pathology laboratories, one may have to rely on archival FFPE material. Procedures to retrieve the RNAs from FFPE materials have been developed and therefore, datasets obtained from FFPE and FF materials need to be made compatible to ensure reliable comparisons are possible. AIM: To develop an efficient method to compare gene expression profiles obtained from FFPE and FF samples using the same platform. METHODS: Twenty-six FFPE-FF sample pairs of the same tumors representing various cancer types, and two FFPE-FF sample pairs of breast cancer cell lines, were included. Total RNA was extracted and gene expression profiling was carried out using Illumina's Whole-Genome cDNA-mediated Annealing, Selection, extension and Ligation (WG-DASL) V3 arrays, enabling the simultaneous detection of 24,526 mRNA transcripts. A sample exclusion criterion was created based on the expression of 11 stably expressed reference genes. Pearson correlation at the probe level was calculated for paired FFPE-FF, and three cut-off values were chosen. Spearman correlation coefficients between the matched FFPE and FF samples were calculated for three probe lists with varying levels of significance and compared to the correlation based on all measured probes. Unsupervised hierarchical cluster analysis was performed to verify performance of the included probe lists to compare matched FPPE-FF samples. RESULTS: Twenty-seven FFPE-FF pairs passed the sample exclusion criterion. From the profiles of 27 FFPE and FF matched samples, the best correlating probes were identified for various levels of significance (Pearson P<0.01, n = 1,432; P<0.05, n = 2,530; and P<0.10, n = 3,351 probes). Unsupervised hierarchical clustering of the 27 pairs using the resulting probes yielded 25, 21, and 19 correctly clustered pairs, respectively, compared to 1 pair when all probes were used. CONCLUSION: The proposed method enables comparison of gene expression profiles of FFPE and/or FF origin measured on the same platform.


Asunto(s)
Perfilación de la Expresión Génica/métodos , Expresión Génica , ARN Mensajero/genética , Análisis por Conglomerados , Perfilación de la Expresión Génica/normas , Humanos , Neoplasias/genética , Especificidad de Órganos/genética
14.
J Alzheimers Dis ; 46(1): 227-38, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25737043

RESUMEN

Increased levels of pregnancy zone protein (PZP) were found in the serum of persons who later developed Alzheimer's disease (AD) in comparison to controls who remained dementia free. We suggested that this increase is due to brain derived PZP entering the blood stream during the early phase of the disease. Here we investigate the possible involvement of PZP in human AD pathogenesis. We observed increased PZP immunoreactivity in AD postmortem brain cortex compared to non-demented controls. In the AD cortex, PZP immunoreactivity localized to microglial cells that interacted with senile plaques and was occasionally observed in neurons. Our data link the finding of elevated serum PZP levels with the characteristic AD pathology and identify PZP as a novel component in AD.


Asunto(s)
Enfermedad de Alzheimer/patología , Placa Amiloide/metabolismo , Placa Amiloide/patología , Proteínas Gestacionales/metabolismo , Anciano , Anciano de 80 o más Años , Péptidos beta-Amiloides/metabolismo , Anticuerpos/metabolismo , Receptor 1 de Quimiocinas CX3C , Cromatografía Liquida , Diagnóstico , Femenino , Proteína Ácida Fibrilar de la Glía/metabolismo , Humanos , Inmunoprecipitación , Masculino , Persona de Mediana Edad , Ovillos Neurofibrilares/metabolismo , Ovillos Neurofibrilares/patología , Fosfopiruvato Hidratasa/metabolismo , Proteínas Gestacionales/genética , Proteínas Gestacionales/inmunología , ARN Mensajero/metabolismo , Receptores de Quimiocina/metabolismo , Espectrometría de Masas en Tándem
15.
J Neuropathol Exp Neurol ; 72(6): 482-8, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23656991

RESUMEN

Mutations in the gene encoding the F-box only protein 7 (FBXO7) cause PARK15, an autosomal recessive form of juvenile parkinsonism. Although the brain pathology in PARK15 patients remains unexplored, in vivo imaging displays severe loss of nigrostriatal dopaminergic terminals. Understanding the pathogenesis of PARK15 might therefore illuminate the mechanisms of the selective dopaminergic neuronal degeneration, which could also be important for understanding idiopathic Parkinson disease (PD). The expression of FBXO7 in the human brain remains poorly characterized, and its expression in idiopathic PD and different neurodegenerative diseases has not been investigated. Here, we studied FBXO7 protein expression in brain samples of normal controls (n = 9) and from patients with PD (n = 13), multiple system atrophy (MSA) (n = 5), Alzheimer disease (AD) (n = 5), and progressive supranuclear palsy (PSP) (n = 5) using immunohistochemistry with 2 anti-FBXO7 antibodies. We detected widespread brain FBXO7 immunoreactivity, with the highest levels in neurons of the cerebral cortex, putamen, and cerebellum. There were no major differences between normal and PD brains overall, but FBXO7 immunoreactivity was detected in large proportions of α-synuclein-positive inclusions (Lewy bodies, Lewy neurites, glial cytoplasmic inclusions), where it colocalized with α-synuclein in PD and MSA cases. By contrast, weak FBXO7 immunoreactivity was occasionally detected in tau-positive inclusions in AD and PSP. These findings suggest a role for FBXO7 in the pathogenesis of the synucleinopathies.


Asunto(s)
Proteínas F-Box/metabolismo , Cuerpos de Inclusión/metabolismo , Atrofia de Múltiples Sistemas/metabolismo , Enfermedad de Parkinson/metabolismo , alfa-Sinucleína/metabolismo , Anciano , Anciano de 80 o más Años , Encéfalo/inmunología , Encéfalo/metabolismo , Encéfalo/patología , Proteínas F-Box/inmunología , Femenino , Células HEK293 , Humanos , Cuerpos de Inclusión/inmunología , Cuerpos de Inclusión/patología , Masculino , Persona de Mediana Edad , Atrofia de Múltiples Sistemas/inmunología , Atrofia de Múltiples Sistemas/patología , Enfermedad de Parkinson/inmunología , Enfermedad de Parkinson/patología , alfa-Sinucleína/inmunología
16.
Cancer Biol Ther ; 13(10): 836-9, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22785212

RESUMEN

Somatic mutation of Isocitrate dehydrogenase 1 (IDH1) at the locus of R132 (IDH1 (R132H)) occurs in > 70% of WHO grade II-III gliomas and secondary glioblastomas. To date it remains unknown whether the mutation is restricted to glial tumor cells. Microglial cells are the resident macrophages in the central nervous system. Tumor-infiltrating microglial cells/macrophages are major stromal cellular components of malignant gliomas and substantially contribute to the tumor mass. Differential identification of the IDH1 (R132H) mutant cellular components is of particular importance for understanding of the mutation-associated tumor biology. Here we discovered that a significant portion of CD68(+), Iba1(+), CX3CR1(+) microglial cells/macrophages also harbor the IDH1R132H mutation. The findings provide novel insights for understanding the mutation-associated tumor biology relevant to clinical applications as a predictive and/or prognostic marker or therapeutic target.


Asunto(s)
Transformación Celular Neoplásica/genética , Glioma/genética , Isocitrato Deshidrogenasa/genética , Macrófagos/metabolismo , Microglía/metabolismo , Mutación , Transformación Celular Neoplásica/metabolismo , Estudios de Cohortes , Glioma/metabolismo , Glioma/patología , Humanos , Isocitrato Deshidrogenasa/metabolismo , Macrófagos/patología , Microglía/patología , Pronóstico
17.
Brain Pathol ; 20(1): 50-65, 2010 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19067716

RESUMEN

In a previous study using state-of-the-art proteomic techniques, we identified colligin 2 (HSP47) as a glioma blood vessel-specific protein. In the present study we precisely localized the expression of colligin 2 in the blood vessels of diffusely infiltrating gliomas and relate the expression to the distinct cellular components of the vessels by using multiple immunolabeling and confocal microscopy. We grouped the glioma blood vessels into morphological categories ranging from normal looking capillaries to vessels with hypertrophic and sclerotic changes. The expression patterns of various markers of endothelial and pericytic differentiation were correlated with the position of the cells in the vessels and the expression of colligin 2. We found that colligin 2 is expressed in all categories of glioma blood vessels in cells with endothelial and pericytic lineage. Expression of colligin 2 was also found in cells scattered around blood vessels and in few glial fibrillary acidic protein-positive cells within the blood vessels. There is overlap in the expression of colligin 2 and the collagens type I and IV for which colligin 2 is a chaperon. We conclude that colligin 2 is expressed in all cellular components of glioma blood vessels and may serve as a general marker for active angiogenesis.


Asunto(s)
Vasos Sanguíneos/metabolismo , Neoplasias Encefálicas/irrigación sanguínea , Neoplasias Encefálicas/metabolismo , Proteínas Portadoras/biosíntesis , Proteínas Portadoras/genética , Glioma/irrigación sanguínea , Glioma/metabolismo , Adulto , Anciano , Biomarcadores de Tumor , Colágeno Tipo I/biosíntesis , Colágeno Tipo IV/biosíntesis , Femenino , Proteína Ácida Fibrilar de la Glía/metabolismo , Glicoproteínas , Humanos , Inmunohistoquímica , Masculino , Microscopía Confocal , Persona de Mediana Edad , Flujo Sanguíneo Regional
18.
Cardiovasc Res ; 81(2): 362-9, 2009 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-18980955

RESUMEN

AIMS: We explored the in vivo effects of knockdown of caldesmon on vascular development in zebrafish. METHODS AND RESULTS: We investigated the effects of caldesmon knockdown on the vascular development in a zebrafish model with special attention for the trunk and head vessels including the aortic arches. We examined the developing fishes at various time points. The vascular abnormalities observed in the caldesmon morphants were morphologically and functionally characterized in detail in fixed and living embryos. The knockdown of caldesmon caused serious defects in vasculogenesis and angiogenesis in zebrafish morphants, and the vascular integrity and blood circulation were concomitantly impaired. CONCLUSION: The data provide the first functional assessment of the role of caldesmon in vascular development in vivo, indicating that this molecule plays a crucial role in vasculogenesis and angiogenesis in vivo. Interfering with caldesmon opens new therapeutic avenues for anti-angiogenesis in cancer and ischaemic cardiovascular disease.


Asunto(s)
Vasos Sanguíneos/embriología , Proteínas de Unión a Calmodulina/fisiología , Animales , Humanos , Neovascularización Fisiológica , Pez Cebra/embriología
19.
Cell Adh Migr ; 1(2): 84-91, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-19329885

RESUMEN

Caldesmon (CaD) is a major actin-binding protein distributed in a variety of cell types. No functional differences among the isoforms in in vitro studies were found so far. In a previous study we found that the low molecular caldesmon isoform (Hela l-CaD) is expressed in endothelial cells (ECs)/endothelial progenitor cells (EPCs) in tumor vasculature of various human tumors. Activation of cell motility is necessary for the navigation of the tip ECs during angiogenesis, and migration of EPCs from the bone marrow during vasculogenesis. In the present study we searched for features of motility and the intracellular expression sites of Hela l-CaD in ECs/EPCs of various human tumors under histologically preserved microenviroment. We discovered a variety of motility-related cell protrusions like filopodia, microspikes, lamellipodia, podosomes, membrane blebs and membrane ruffles in the activated ECs/EPCs. Hela l-CaD appeared to be invariably expressed in the subregions of these cell protrusions. The findings suggest that Hela l-CaD is implicated in the migration of ECs/EPC in human neoplasms where they contribute to tumor vasculogenesis and angiogenesis.


Asunto(s)
Proteínas de Unión a Calmodulina/metabolismo , Movimiento Celular , Células Endoteliales/citología , Neoplasias/metabolismo , Neoplasias/patología , Células Madre/citología , Proteínas de Unión a Calmodulina/genética , Membrana Celular/metabolismo , Gelsolina/metabolismo , Células HeLa , Humanos , Neoplasias/irrigación sanguínea , Neoplasias/genética , Neovascularización Patológica
20.
Cancer ; 106(2): 388-95, 2006 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-16342252

RESUMEN

BACKGROUND: The results of attempts to identify histopathologic parameters that contribute to the clinical outcome of patients with ependymomas have been controversial. This may be due to the relative rareness of ependymomas. Furthermore, in many investigations, myxopapillary ependymomas and subependymomas were included and may have confounded results, because those tumors should be considered clinicopathologic entities distinct from the other ependymomas. METHODS: In this retrospective study, the influence of the histologic subtype of ependymoma and of individual histologic features on the outcome of 69 patients with ependymomas was investigated. Myxopapillary ependymomas, subependymomas, and ependymomas with spinal localizations were excluded from the analysis. The ependymomas were subdivided into cellular, papillary, clear cell, and tanycytic subtypes. The study extended over a period of 30 years. RESULTS: No differences in clinical outcome between the four histologic subtypes of ependymomas were revealed. Neither tumor localization (either infratentorial or supratentorial), patient age, nor gender affected survival. The survival of patients who underwent complete tumor resection differed significantly from that of patients who underwent partial resection. In univariate analysis, the features of nuclear atypia, the mitotic index, and the MIB-1 labeling index (LI) significantly influenced survival. With regard to survival, the presence of microcysts, blood vessel density, and the feature of vascular hyalinization demonstrated a trend but did not reach significance. In multivariate analysis, only the mitotic index and the MIB-1 LI were identified as factors with independent prognostic significance (P = 0.027 and P = 0.023, respectively). Both proliferation indices were correlated strongly with each other. CONCLUSIONS: The results of the univariate analysis indicated that, for patients with intracranial ependymoma, nuclear atypia, the mitotic index, and the MIB-1 LI significantly influenced survival. In the multivariate analysis, the mitotic index and the MIB-1 LI were the only features that had independent prognostic significance. Because both showed strong correlations, only one of them should be included in a grading scheme for intracranial ependymomas.


Asunto(s)
Neoplasias Encefálicas/mortalidad , Neoplasias Encefálicas/patología , Ependimoma/mortalidad , Ependimoma/patología , Glioma Subependimario/mortalidad , Glioma Subependimario/patología , Adolescente , Adulto , Anciano , Anticuerpos Antinucleares/inmunología , Anticuerpos Monoclonales/inmunología , Neoplasias Encefálicas/inmunología , Niño , Preescolar , Ependimoma/inmunología , Femenino , Glioma Subependimario/inmunología , Humanos , Lactante , Recién Nacido , Antígeno Ki-1/análisis , Masculino , Persona de Mediana Edad , Pronóstico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA